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Background: We examined whether silencing of IGFBP7 was associated with survival in patients with oesophageal
adenocarcinoma.
Methods: Protein expression of IGFBP7 was determined using immunohistochemistry in a tissue microarray representing tumours
from 65 patients with oesophageal adenocarcinoma who had not had neoadjuvant therapy. DNA methylation of the IGFBP7
promoter was determined with the melt curve analysis in cell lines and patient tissues.
Results: Expression of IGFBP7 was observed in the oesophageal adenocarcinoma of 34 out of 65 (52%) patients and was
associated with significantly reduced median (11 vs 92 months) and 5-year survival (25% vs 52%). Multivariate analysis identified
expression as an independent prognostic indicator for survival (hazard ratio¼ 3.24, 95% confidence interval¼ 1.58–6.67,
P-value¼ 0.0014). Hypermethylation of IGFBP7 was associated with silencing of gene expression in cell lines and patient tissues
(P-value¼ 0.0225). Methylation was observed in the squamous mucosa of 2 out of 15 (13%) patients with Barrett’s oesophagus and
3 out of 17 (18%) with oesophageal adenocarcinoma. Methylation was observed in 14 out of 18 (78%) of biopsies of Barrett’s
mucosa and 23 out of 34 (68%) patients with oesophageal adenocarcinoma.
Conclusion: Reduced IGFBP7 protein expression was associated with longer survival in patients with oesophageal
adenocarcinoma. Methylation of the IGFBP7 promoter was associated with silencing of gene expression and was frequent in
Barrett’s oesophagus and oesophageal adenocarcinoma.
Oesophageal adenocarcinoma has increased rapidly in incidence in
the Western world over recent decades and continues to have a
poor prognosis, with 5-year survival rates of o10% (Umar and
Fleischer, 2008). Approximately 0.1–0.3% of patients with the
premalignant lesion Barrett’s oesophagus will develop oesophageal
adenocarcinoma each year (Bhat et al, 2011; Hvid-Jensen et al,
2011). The majority of patients present with late-stage disease that
is not amenable to resection and have a poor response to non-
surgical therapy.
The insulin-like growth factor (IGF) signalling pathway has a
key role in mediating normal growth and development, and in the
malignant progression of many cancers including oesophageal
adenocarcinoma (Doyle et al, 2012). The IGF system involves
the complex coordination of growth factors (IGF1 and IGF2), cell
surface receptors (IGF1R, IGF2R and INSR), high- and low-affinity
IGF-binding proteins (IGFBPs), as well as the IGFBP-degrading
proteases. The IGFBPs serve as carrier proteins for IGFs,
prolonging their half-life and modulating their binding to the
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IGF receptors. Some IGFBP proteases cleave IGFBPs, release IGFs,
and increase signalling. IGFBP7 is one of 16 members of the
IGFBP superfamily of proteins. It binds IGFs with relatively low
affinity but binds insulin with very high affinity (500-fold higher
than other IGFBPs) (Burger et al, 2005).
Changes in DNA methylation are frequent, early events in
carcinogenesis, widely present even in premalignant lesions such as
Barrett’s oesophagus (Smith et al, 2008, 2010). Hypermethylation
in promoter regions is associated with gene silencing, whereas
hypomethylation in other regions is associated with genomic
instability. DNA methylation is of clinical interest because it may
lead to biomarkers for early detection, diagnosis, prognosis,
therapeutic stratification, and post-therapeutic monitoring. Down-
regulation of IGFBP7 with promoter DNA methylation has been
demonstrated in various cancers (Komatsu et al, 2000; Ruan et al,
2006; Lin et al, 2007; Jiang et al, 2008; Lin et al, 2008; Hinoue et al,
2009; Suzuki et al, 2010; Heesch et al, 2011; Chen et al, 2011b;
Sullivan et al, 2012; Dimberg et al, 2013; Suzuki et al, 2013) but has
not been previously reported in Barrett’s oesophagus or oesopha-
geal adenocarcinoma.
Here we report the correlation between IGFBP7 expression and
clinicopathological parameters, including survival, in patients with
oesophageal adenocarcinoma, and the association between IGFBP7
expression and DNA methylation in oesophageal adenocarcinoma
and Barrett’s oesophageal cell lines and tissues.
MATERIALS AND METHODS
Tissue microarrays and immunohistochemistry. Tissue micro-
arrays (TMAs) were constructed as previously described
(Thompson et al, 2011). Sections (4 mm) were mounted on
polylysine-coated slides, dewaxed and rehydrated. Antigen retrieval
was performed by heating the sections for 5min in 10mmol l 1
citrate buffer (pH 6) in a microwave pressure cooker. After cooling
to room temperature, sections were immunostained using an
Autostainer Plus (Dako, Glostrup, Denmark). Sections were
incubated for 60min with a 1 : 75 dilution of rabbit anti-human
IGFBP7 polyclonal IgG antibody (H-102; Santa Cruz Biotechnology
Inc., Santa Cruz, CA, USA) and then with MACH 4 Universal
Horseradish Peroxidase-Polymer (Biocare Medical, Concord,
CA, USA). Liquid 3,3-diaminobenzidine (Dako) was used as the
chromogen, and sections were counterstained with Meyer’s
haematoxylin. The expression of IGFBP7 was scored as positive
(present) or negative (absent) by an experienced gastrointestinal
pathologist (ARR).
Cell lines. Human oesophageal adenocarcinoma (OE33, OE19,
and JH-EsoAd1 (Alvarez et al, 2008)) and squamous cell
carcinoma (OE21 and TE7 (Nishihira et al, 1993)) cell lines were
maintained in RPMI-1640 supplemented with 10% foetal bovine
serum, 4mmol l 1 L-glutamine, 200Uml 1 penicillin, and
200 mgml 1 streptomycin at 37 1C in a humidified incubator with
5% CO2 in air. The human telomerase immortalised Barrett’s
oesophagus epithelial cells, CP-A, CP-B, and CP-D were main-
tained as previously described (Palanca-Wessels et al, 1998). The
nontumourigenic SV40T-transformed squamous oesophageal cell
line HET1A (Stoner et al, 1991) was maintained as previously
described (Underwood et al, 2010). All cell lines were cultured at
37 1C in a humidified incubator with 5% CO2 in air. To study the
effects of demethylation, triplicate cultures were treated with either
1mmol l 1 5-aza-2’-deoxycytidine (aza, Sigma-Aldrich, St Louis,
MO, USA) or vehicle (veh; 0.0027% v/v final concentration acetic
acid), as described previously (Smith et al, 2005, 2008).
Patient samples. Multiple biopsies every 2 cm from within
circumferential columnar lined oesophagus (n¼ 40) and a single
biopsy of squamous mucosa proximal to the squamocolumnar
junction (n¼ 15) from 18 patients with Barrett’s oesophagus were
collected into RNAlater. For a diagnosis of Barrett’s oesophagus,
goblet cells had to be observed in at least one biopsy from the
columnar-lined oesophagus. All patients with Barrett’s oesophagus
were being treated for gastro-oesophageal reflux disease with anti-
secretory therapy. Single samples of primary tumour oesophageal
adenocarcinoma (n¼ 34), adjacent high-grade dysplasia (n¼ 7),
and histologically normal squamous mucosa from the proximal
resection margin (n¼ 17) from 34 patients with oesophageal
adenocarcinoma were collected into liquid nitrogen or into
RNAlater (Ambion, Austin, TX, USA). The study complied with
the appropriate institutional guidelines.
Isolation of RNA and DNA from cell lines and patient
samples. Patient tissues were disrupted in either disposable pestles
(Edwards Instruments, Narellan, NSW, Australia) or a TissueLyser
with 5-mm stainless steel beads (Qiagen, Hilden, Germany). The
RNA and DNA were isolated from cell lines and oesophageal
adenocarcinoma patient tissues using Trizol (Invitrogen, Carlsbad,
CA, USA) and from all other biopsies using either the RNA/DNA
Kit or the AllPrep DNA/RNA Mini Kit (Qiagen).
Methylation analysis. Genomic DNA (500 ng) was bisulphite-
modified using the EZ DNA Methylation-Gold Kit (Zymo
Research, Irvine, CA, USA). The bisulphite-modified DNA was
amplified using primer sets, which did not discriminate between
methylated and unmethylated sequences. The primer sequences
were (forward) 50-GGGTTGTTTGTTGGGYGAGATT-30 and
(reverse) 50-ACTTTACCCTTCCRCCTCTTAC-30. The primers
and PCR conditions were specific for bisulphite-modified DNA
and did not amplify unmodified DNA. All methylation analysis
PCRs were performed using the QuantiTect SYBR Green PCR Kit
(Qiagen) in a final volume of 15 ml, containing 1ml of bisulphite-
modified DNA and a final concentration of 0.5mmol l 1 of each
forward and reverse primer. Bisulphite-modified lymphocyte
DNA, CpG methyltransferase (M.SssI) (New England Biolabs
Inc, Ipswich, MA, USA) treated lymphocyte DNA, and unmodified
DNA were included in each PCR run and served as unmethylated,
methylated, and negative controls, respectively. Reactions were run
in a Rotor-Gene 3000 (RG-3000) (Corbett Life Science, Sydney,
NSW, Australia) at 95 1C for 15min, then 45 cycles of 95 1C for
30 s and 59 1C for 60 s, followed by a final extension of 72 1C for
4min. At the end of the amplification cycle, the PCR products were
melted by increasing the temperature from 60 to 95 1C, rising
0.5 1C at each step, waiting 30 s on the first step and then 5 s for
each step thereafter. The raw fluorescence data were normalised as
previously described (Smith et al, 2009). Methylation was also
measured using an Infinium HumanMethylation450 BeadChip
Kit (Illumina, San Diego, CA, USA), as previously described (Lim
et al, 2013).
Measurement of gene expression by quantitative real-time
reverse-transcription PCR. To measure gene expression, cDNA
was synthesised using SuperScript II (Invitrogen) from 2mg of total
RNA that had been treated with the TURBO DNA-free Kit
(Ambion). Quantitative real-time reverse-transcription polymerase
chain reaction (QPCR) was performed using the QuantiTect SYBR
Green PCR Kit in a final volume of 10 ml, containing 0.2 ml of
cDNA and a final concentration of 0.5 mmol l 1 of each forward
and reverse primer. The primer sequences were (forward) 50-AGC
TGTGAGGTCATCGGAAT-30 and (reverse) 50-ACCAGCACCCA
GCCAGTTA-30. Triplicate reactions were run in an RG-3000 at
95 1C for 15min, then 45 cycles of 95 1C for 30 s and 57 1C for 60,
followed by a final extension of 72 1C for 4min. Data were
collected and analysed using the RG-3000 Application Software.
Threshold cycle Ct values were determined on auto-threshold
settings with reference to a standard dilution curve. All mRNA
quantitation data were normalised to hydroxymethylbilane
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synthase (HMBS). Following the PCR, the products were melted
to confirm specificity and electrophoresed on 1.5% (w/v)
agarose gels stained with ethidium bromide to confirm expected
product size.
Statistical analyses. Statistics were performed using SAS Version
9.2 (SAS Institute Inc., Cary, NC, USA) and Prism version 6.0b
for Macintosh (GraphPad Software, San Diego CA, USA; www.
graphpad.com). The median overall survival and the 5-year
survival were calculated using the Kaplan–Meier estimator.
Kaplan–Meier survival curves were compared using the Log-rank
(Mantel–Cox) test. Hazard ratios (HRs), 95% confidence intervals
(CIs), and P-values were calculated from univariate and multi-
variate Cox proportional hazards models. Gene expression in cell
lines comparing treatment with aza to veh was performed using
multiple t-tests and significance determined using the
Holm–Sidak method, with alpha of 5%. Methylation frequency
in tissues and the correlation between methylation and expression
was compared using Fisher’s exact test. All statistics were
considered significant when the two-tailed P-value was p0.05.
RESULTS
Expression of IGFBP7 in oesophageal adenocarcinoma and
Barrett’s oesophagus. The protein expression of IGFBP7 was
measured using immunohistochemistry in oesophageal adenocar-
cinoma resections from 65 patients. None of the patients had
preoperative chemotherapy or radiotherapy. Follow-up data were
available from all patients, with a median follow-up time of 33
months (range 1–149). The median patient age at surgery was 63
years (range 35–80). The overall 5-year survival rate was 28%, and
the overall median survival was 27 months (range 1–129).
Positive staining for IGFBP7 in tumour cells was observed in 34
of 65 (52%) patients (Figure 1). In positive tumour cells, staining
was localised to the cytoplasm and was uniformly of moderate
intensity. Sporadic staining of positive stromal cells, including
endothelial cells, was localised to the cytoplasm and ranged in
intensity from weak to intense.
Expression of IGFBP7 protein was associated with decreased
patient survival (Figure 2). With univariate analysis, IGFBP7
positivity, advanced pT stage, lymph node metastases, a positive
resection margin, and vascular and perineural invasion were
significantly associated with decreased survival (Table 1). Expres-
sion of IGFBP7 was associated with a significant decrease in the
median overall survival (11 vs 92 months; P-value¼ 0.0140) and
decreased 5-year survival (24.5% vs 51.6%), (HR¼ 2.16; 95%
CI¼ 1.14–4.09; P-value¼ 0.0177).
Owing to the limited number of patients, only IGFBP7
expression, pT, pN, and positive resection margin were retained
in the multivariate model (Table 1). The prognostic value of
IGFBP7 expression, pT stage, and a positive resection margin were
maintained even after adjustment for the other covariates,
supporting the independent role of these markers in predicting
survival. Survival was significantly reduced for patients who were
Figure 1. Immunohistochemistry of IGFBP7 in human oesophageal adenocarcinoma. Representative images of IGFBP7 immunohistochemistry
displaying (A) negative expression in tumour cells and stroma; (B) negative expression in tumour cells, and positive in stroma; (C) positive



















Figure 2. Kaplan–Meier analysis of overall survival of patients
with oesophageal adenocarcinoma in relation to IGFBP7
expression. Expression of IGFBP7 in tumour cells, determined by
immunohistochemistry, scored as negative (n¼31) or positive
(n¼ 34). Log-rank (Mantel–Cox) test P-value¼0.0140.
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positive compared with those who were negative for IGFBP7
expression (HR¼ 3.25; 95% CI¼ 1.58–6.67; P-value¼ 0.0014).
Next, we analysed IGFBP7 mRNA expression in normal
oesophagus, Barrett’s oesophagus, and oesophageal adenocarci-
noma in published transcription microarray data sets. There was a
significant increase in IGFBP7 mRNA in adenocarcinoma (four of
four data sets) and Barrett’s oesophagus (three of four), compared
with normal oesophageal tissue (Figure 3). Despite the significant
increase in expression in oesophageal adenocarcinoma, it was
clear that there was a wide range of expression from low to high,
consistent with our finding that IGFBP7 was only expressed in a
subset of patients. Some clinical data were available for one of the
public data sets (Kim et al, 2010), and the expression of IGFBP7
was significantly increased in stage 3 tumours compared with stage 0;
however, no other significant differences were observed.
DNA methylation and expression of IGFBP7 in oesophageal cell
lines. The melt curve analysis was used to measure the extent
of DNA methylation, and QPCR to measure expression, of IGFBP7
in three oesophageal cancer cell lines. OE21 and TE7 were
unmethylated and expressed IGFBP7, whereas OE33 was methylated
and did not express the gene (Figure 4). When OE33 was grown in
the presence of aza, the extent of DNA methylation decreased, and
the expression of IGFBP7 significantly increased (P-valueo0.0001).
In contrast, aza did not significantly alter IGFBP7 DNA methylation
or expression in either OE21 and TE7. Methylation of IGFBP7 in
OE33 was also assessed on an Infinium HumanMethylation450
BeadChip Kit (Figure 4C). All CpG probes assessed within the
promoter region ( 500 to þ 1000 nt from the transcription start site)
were heavily methylated, with beta-values 40.8. Together, these
results are consistent with methylation of the region of IGFBP7
assessed with the melt curve analysis being associated with
silencing of its expression in oesophageal cell lines.
Methylation was also assessed in the following oesophageal
cell lines: oesophageal adenocarcinoma (OE19, JH-EsoAd1),
telomerase immortalised non-dysplastic (CP-A), and high-grade







HR (95% CI) P-value
Multivariate
HR (95% CI) P-value
IGFBP7 expression
Negative 31 92 51.61 1 1
Positive 34 11 24.51 2.163 (1.143-4.093) 0.0177 3.247 (1.580–6.673) 0.0014
Gender
Female 9 10 11.11 1
Male 56 40 42.34 0.514 (0.235–1.126) NS
Age
o70 46 38.5 40.82 1 —
X70 19 22 31.58 1.471 (0.771–2.807) NS
pT stage
T1a/1b 15 — 86.67 1
T2 10 65 50.00 6.107 (1.227–30.395) 0.0271 7.068 (1.411–35.407) 0.0174
T3 31 20 22.12 9.304 (2.185–39.621) 0.0026 19.423 (2.478–152.243) 0.0047
T4 9 5 0.00 24.894 (5.223–118.637) o0.0001 27.357 (3.143–238.134) 0.0027
pN
0 28 — 67.86 1 1
1 37 — 15.77 3.603 (1.754–7.402) 0.0005 3.951 (1.182–13.208) 0.0256
Grade of differentiation
Well/moderate 19 — 51.46 1
Poor/undifferentiated 46 20 30.95 1.975 (0.941–4.147) NS
Resection margin
Negative 34 — 63.89 1 1
Positive 31 9 9.68 4.503 (2.301–8.810) o0.0001 3.951 (1.182–13.208) 0.0256
Vascular invasion
No 18 — 71.30 1
Yes 47 16 25.35 4.171 (1.625–10.708) 0.0030
Perineural invasion
No 35 — 57.14 1
Yes 30 10.5 15.56 2.503 (1.329–4.715) 0.0045
Abbreviations: CI¼ confidence interval; HR¼ hazard ratio; NS¼ not significant; pT stage¼pathological tumour stage.
aMedian survival/5-year survival calculated using the Kaplan–Meier estimator.
bMedian survival could not always be estimated as o50% death in some subgroups.
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dysplastic (CP-B, CP-D) Barrett’s oesophagus, and immortalised
squamous epithelium (HET1A). Methylation was detected in
OE19, JH-EsoAd1, and CP-A, but not in CP-B, CP-D nor HET1A
(Figure 4D). We found that methylation of IGFBP7 is a common
feature of Barrett’s and oesophageal adenocarcinoma cell lines.
DNA methylation of IGFBP7 in Barrett’s oesophagus and
oesophageal adenocarcinoma tissues. Methylation was deter-
mined using the melt curve analysis in biopsies of squamous
mucosa and columnar lined oesophagus from 18 patients with
Barrett’s oesophagus. Methylation was detected in significantly
more biopsies of columnar lined oesophagus (27 of 40; 68%) than
squamous mucosa (2 of 15; 13%) (P-value¼ 0.0006). Methylation
was detected in at least one biopsy of columnar lined oesophagus
in 14 of 18 (78%) patients with Barrett’s oesophagus.
Methylation was determined in biopsies of tumour, and when
available, adjacent high-grade dysplasia, and histologically normal
squamous proximal resection margin from 34 patients with
oesophageal adenocarcinoma. Compared with squamous mucosa
(3 of 17; 18%), methylation was detected in significantly more
biopsies of high-grade dysplasia (5 of 7; 71%) (P-value¼
0.0207) and oesophageal adenocarcinoma (23 of 34; 68%)
(P-value¼ 0.0010). Together, these results demonstrate that IGFBP7
methylation is infrequent in squamous mucosa but is common in
Barrett’s oesophagus and oesophageal adenocarcinoma tissue.
Matched DNA methylation and expression data were available
for 22 of the 65 patients. Methylation was detected in seven out of
seven (100%) patients who did not express IGFBP7, compared with
47% (7 of 15) patients who did (P-value¼ 0.0225). Survival was
reduced in patients with unmethylated IGFBP7 (9 vs 56 months;
Figure 5); however, this difference was not significant (log-rank
test, P-value¼ 0.071; Cox proportional hazards model, HR¼ 0.46,
95% CI¼ 0.19–1.10).
DISCUSSION
We have demonstrated that, in patients with oesophageal
adenocarcinoma, protein expression of IGFBP7 was associated
with significantly reduced survival, independent of other clinico-
pathological features. In both oesophageal adenocarcinoma and
Barrett’s cell lines, DNA methylation within the IGFBP7 promoter
was associated with transcriptional silencing. In patient samples,
DNA methylation of IGFBP7 was infrequent in squamous mucosa,
but a common feature in Barrett’s and oesophageal adenocarci-
noma, and it correlated with silencing of protein expression.
The levels of expression of IGFBP7 differ among different
cancer types. Increased expression has been observed in glioblas-
toma multiforme (Jiang et al, 2008), oesophageal squamous cell
(Kashyap et al, 2012), and colorectal carcinoma (Umeda et al,
1998). In Barrett’s and oesophageal adenocarcinoma samples we
found, from an analysis of four independent expression array data
sets in public repositories, that IGFBP7 transcript expression was
increased in a proportion of patient samples compared with their
squamous mucosa, consistent with our immunohistochemical
findings. In contrast, decreased expression has been reported in
cancers of the breast (Burger et al, 1998), lung (Chen et al, 2007),
prostate (Hwa et al, 1998), pancreas (An et al, 2012), liver (Chen
et al, 2011a), and thyroid (Vizioli et al, 2010), raising the possibility
that, at least in some types of cancer, IGFBP7 may function as a
tumour suppressor. A limitation of our correlative study is that the
data do not allow any conclusions to be reached regarding the
possible biological role of IGFBP7 in oesophageal adenocarcinoma.
Decreased IGFBP7 expression has been associated with DNA
methylation in a range of cancers including T-lymphoblastic
leukaemia (Heesch et al, 2011), liver (Komatsu et al, 2000), lung
(Chen et al, 2011b; Suzuki et al, 2013), prostate (Sullivan et al,
2012), and colorectal (Ruan et al, 2006; Lin et al, 2007, 2008;
Hinoue et al, 2009; Suzuki et al, 2010; Dimberg et al, 2013), as well
as premalignant colorectal adenomas (Kaji et al, 2012). In our
study, methylation was detected in oesophageal adenocarcinoma
and Barrett’s oesophagus cell lines. The methylation was associated
with decreased transcript expression, and demethylation with
5-aza-20-deoxycytidine resulted in IGFBP7 re-expression. Methyla-
tion was more frequently observed in primary Barrett’s and
oesophageal adenocarcinoma tissues than in adjacent histologically
normal squamous mucosa. Finally, methylation in adenocarcinoma
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Figure 3. Expression of IGFBP7 in oesophageal tissues. Expression of IGFBP7 in histologically normal squamous mucosa (Normal), Barrett’s
oesophagus (Barrett’s), and oesophageal adenocarcinoma (OAC) tissues was determined using transcriptional microarrays in four different data
sets as named and published on Oncomine.
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Taken together, these data demonstrate that DNA methylation of
the IGFBP7 promoter is associated with the silencing of its
expression and is common in Barrett’s and adenocarcinoma of the
oesophagus.
Reports on the prognostic significance of IGFBP7 expression in
cancer are conflicting. In accordance with our findings, increased
expression of IGFPB7 was associated with decreased patient
survival in colorectal (Adachi et al, 2001), T-acute lymphoblastic
leukaemia (Heesch et al, 2010), and head and neck squamous cell
carcinoma (Sepiashvili et al, 2012). In contrast, increased
expression correlated with increased survival in pancreatic ductal
(An et al, 2012), breast (Landberg et al, 2001), hepatocellular
(Tomimaru et al, 2012), and colorectal carcinoma (Ruan et al,
2007). These conflicting observations may be because of hetero-
geneous expression within the cancer. For example, Adachi et al
(2001) reported that expression was greatest in the cells located at
the invasive front of tumour nests, and that it was the expression in
these cells that correlated with poor patient prognosis, independent
of other clinicopathological covariates. In our study, we could not
be confident that the increased expression that we observed was
restricted to the cells at the invasive front because we stained
TMAs that were constructed using 1mm cores taken from
representative regions of the tumour, which did not always include
the invasive front.
In conclusion, expression of IGFBP7 was an independent
prognostic indicator for decreased patient survival in oesophageal
adenocarcinoma. DNA methylation within the IGFBP7 promoter
was associated with transcriptional silencing in oesophageal
adenocarcinoma and Barrett’s cell lines, was a common feature
in Barrett’s and oesophageal adenocarcinoma tissues, and corre-
lated with silencing of protein expression.
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